Liquidia Corp
LQDA
About: Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Employees: 170
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
64% more call options, than puts
Call options by funds: $27.4M | Put options by funds: $16.7M
37% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 27
16% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 56
5% more funds holding
Funds holding: 168 [Q1] → 177 (+9) [Q2]
3.12% more ownership
Funds ownership: 64.18% [Q1] → 67.29% (+3.12%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 8 [Q1] → 8 (+0) [Q2]
11% less capital invested
Capital invested by funds: $808M [Q1] → $717M (-$90.7M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Jefferies
Amy Li
|
$43
|
Buy
Assumed
|
15 Aug 2025 |
|
Raymond James
Ryan Deschner
|
$41
|
Strong Buy
Maintained
|
13 Aug 2025 |
|
Wells Fargo
Tiago Fauth
|
$31
|
Overweight
Maintained
|
13 Aug 2025 |
|
Needham
Serge Belanger
|
$36
|
Buy
Maintained
|
12 Aug 2025 |
Financial journalist opinion
